-
Chardan Capital Downgrades Globalstar On Monetization Concerns
Thursday, August 9, 2018 - 2:01pm | 303Read More...Mobile satellite voice and data services provider Globalstar, Inc. (NYSE: GSAT) called off its merger with Thermo Acquisitions Aug. 1, and the company reported a $7-million loss in its second-quarter print Aug. 2. The Analyst Chardan Capital's James McIlree downgraded...
-
Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy
Wednesday, February 21, 2018 - 10:18am | 382Read More...The young biotech firm Solid Biosciences Inc (NASDAQ: SLDB) secured two Buy ratings Tuesday and another Wednesday. The Rating Chardan Capital analyst Gbola Amusa initiated Solid Biosciences with a Buy rating and $40 price target. The Thesis Amusa expects gene therapies to penetrate 26.8...
-
5 Reasons Why Vuzix Is One Of Chardan Capital's Top Picks In 2018
Monday, January 8, 2018 - 6:26pm | 536Read More...Vuzix (NASDAQ: VUZI) is set to unveil its Blade smart glasses at CES 2018. Ahead of the conference, shares rallied about 24 percent as details of what would be discussed at CES emerged. The Analyst Chardan Capital analyst James McIlree called Vuzix one of the firm’s top picks for 2018 and...
-
8 Ways To Play The AI Boom
Tuesday, September 26, 2017 - 9:24am | 983Read More...Investors hungry for pure-play artificial intelligence companies have sent share prices of a handful of smaller tech companies soaring in recent weeks. Here’s a look at eight stocks with an emphasis on AI that may still be mostly under-the-radar. 1. Veritone Benzinga first reported about...
-
Here's What Makes La Jolla Pharma A 2017 Top Pick At Chardan
Tuesday, January 24, 2017 - 3:01pm | 323Read More...Chardan Capital names La Jolla Pharmaceutical Company (NASDAQ: LJPC) as its Top Pick for 2017,saying the company has shown one of the more compelling and convincing rare disease strategies in biotech. “By focusing on naturally-occurring peptides with well-established biological functions,...
-
Which Wet AMD Stock Would You Buy Right Now?
Wednesday, December 14, 2016 - 12:30pm | 441Read More...Shares of Ophthotech Corp (NASDAQ: OPHT) tanked more than 80 percent on Monday after the company announced that the primary endpoint in two Phase 3 trials exploring its Fovista® therapy was not met. Fovista is Ophthotech's therapy intended to be administered in combination with an anti VEGF agent...
-
UniQure Vs. Spark Therapeutics: One Has Better Timing, The Other Has Better Efficacy
Monday, December 5, 2016 - 2:15pm | 349Read More...Gbola Amusa of Chardan Capital said although the AAV-based gene therapy (GT) of Uniqure NV (NASDAQ: QURE has better timing, Spark Therapeutics Inc (NASDAQ: ONCE)has better efficacy in hemophilia B patients. Amusa gave the above comments after both companies presented their data at The American...
-
5 Reasons Arrowhead Pharma Is A Hepatitis B Leader
Thursday, May 19, 2016 - 12:38pm | 283Read More...Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) reported positive data in a Phase II study of its lead product ARC-520 for the treatment of hepatitis B surface antigen [HBsAg] in HB envelope antigen-positive [HBeAg+] HBV patients. Chardan Capital’s Madhu Kumar initiated coverage of the company...
-
Why Regeneron's Praluent Is Likely To Be Removed From The U.S. Market This Year
Monday, March 21, 2016 - 11:08am | 198Read More...Chardan Capital’s Gbola Amusa maintained a Sell rating for Regeneron Pharmaceuticals Inc (NASDAQ: REGN), with a price target of $325, mentioning that Praluent is likely to be removed from the US market in 2016. Growth Offset Although the anti-PCKS9 market is expected to grow to $16.4...
-
Digital Ally Falls 5% After Big Earnings Miss
Monday, March 7, 2016 - 4:30pm | 152Read More...Early Monday afternoon, Digital Ally, Inc. (NASDAQ: DGLY) reported quarterly results. The release may have been come sooner than planned.Falls Q4's EPS came in at $(0.40) versus an estimated $(0.18). Sales came in at $5.051 million versus the estimated $5.70 million. Following this...
-
Guidance Cut Could Sent Ambarella's Downward Spiral Lower
Monday, March 7, 2016 - 9:29am | 234Read More...Chardan Capital’s Marc Estigarribia maintained a Neutral rating for Ambarella Inc (NASDAQ: AMBA), while reducing the price target from $90 to $50. Ambarella has the potential to return to a healthy, above-market-average CAGR in sales, earnings and FCF, driven by the strength of its video...
-
Chardan Upgrades Regeneron Amid Relative Underperformance To Amgen Shares
Tuesday, February 16, 2016 - 9:33am | 330Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares have been trending south in 2016, and are down 30 percent since January 4. Chardan Capital’s Gbola Amusa upgraded the rating for the company from Sell to Neutral, while reducing the price target from $400 to $375. Regeneron’s...
-
Chardan Is Buying CEVA, Low End Smartphone/LTE Upgrade Cycles In China & India Offer 'Tremendous Opportunity'
Thursday, February 4, 2016 - 9:50am | 270Read More...CEVA, Inc (NASDAQ: CEVA) shares have been trending lower in recent months, and have lost 17 percent since November 4. Chardan Capital’s Marc Estigarribia maintained a Buy rating for the company, with a price target of $27. The company is well positioned to benefit from growth in...
-
Chardan Initiates Eyegate Pharma At Buy, Sets $6 Target
Wednesday, December 23, 2015 - 8:54am | 331Read More...Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares are down 30 percent in the last three months, and have traded below $3 for most of December. Chardan Capital’s Keay Nakae initiated coverage of the company with a Buy rating and a price target of $6. Eyegate Pharma’s lead...
-
Chardan Thinks CalAmp Stock Is A Buy
Monday, December 7, 2015 - 9:21am | 307Read More...Shares of CalAmp Corp. (NASDAQ: CAMP) have been volatile in 2015 and are down 2 percent in the last one month. Chardan Capital’s Marc Estigarribia initiated coverage of the company with a Buy rating and a price target of $24. The company is poised to benefit from the increasing...
